Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
42
PETS Quote, Financials, Valuation and Earnings
Last price:
$4.98
Seasonality move
:
7.36%
Day range:
$4.94 - $5.35
52-week range:
$2.90 - $7.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
1.07x
Volume:
541.3K
Avg. volume:
304.1K
1-year change:
-32.2%
Market cap:
$102.7M
Revenue:
$281.1M
EPS (TTM):
-$0.06
Analysts' Opinion
-
Consensus RatingPetMed Express has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, PetMed Express has an estimated downside of -24.55% from its current price of $4.97.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $4.97.
Fair Value
-
According to the consensus of 0 analysts, PetMed Express has -24.55% downside to fair value with a price target of -- per share.
PETS vs. S&P 500
-
Over the past 5 trading days, PetMed Express has underperformed the S&P 500 by -7.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PetMed Express does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PetMed Express revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter PetMed Express reported revenues of $59.6M.
Earnings Growth
-
PetMed Express has grown year-over-year earnings for 1 quarter straight. In the most recent quarter PetMed Express reported earnings per share of $0.11.
Enterprise value:
50.7M
EV / Invested capital:
0.53x
Price / LTM sales:
0.40x
EV / EBIT:
--
EV / Revenue:
0.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-55.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
9.98x
Gross Profit (TTM):
$71.3M
Return On Assets:
-0.6%
Net Income Margin (TTM):
-0.37%
Return On Equity:
-0.96%
Return On Invested Capital:
-0.96%
Operating Margin:
0.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $261M | $270.5M | $259.3M | $71M | $59.6M | |
| Gross Profit | $74.2M | $75.2M | $71.3M | $20.1M | $17.3M | |
| Operating Income | $17.1M | -$2.2M | -$2M | $875K | $554K | |
| EBITDA | $20.1M | $3.1M | $5.1M | $2.6M | $2.2M | |
| Diluted EPS | $0.77 | -$0.29 | -$0.06 | $0.03 | $0.11 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.6M | $133.4M | $138.2M | $85.7M | $70.8M | |
| Total Assets | $158.9M | $159.4M | $169.3M | $159.3M | $146M | |
| Current Liabilities | $21.2M | $16.3M | $30.6M | $40.7M | $48.8M | |
| Total Liabilities | $22.5M | $17.9M | $31.1M | $45.6M | $49.6M | |
| Total Equity | $136.4M | $141.5M | $138.2M | $113.7M | $96.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $22.5M | $22.5M | $3.4M | -$777K | $7.4M | |
| Cash From Investing | -$8.1M | -$40.9M | -$4.6M | -$984K | -$1.3M | |
| Cash From Financing | -$24.4M | -$24.6M | -$208K | -$6.3M | -$71K | |
| Free Cash Flow | $19.4M | $17.4M | -$918K | -$1.8M | $6.1M | |
PETS
Sector
Market Cap
$102.7M
$483.3M
Price % of 52-Week High
63.8%
72.36%
Dividend Yield
0%
0%
Shareholder Yield
--
3.61%
1-Year Price Total Return
-32.2%
-11.07%
Beta (5-Year)
0.711
0.973
Dividend yield:
0%
Annualized payout:
$0.60
Payout ratio:
-21.6%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.45
200-day SMA
Buy
Level
$4.19
Bollinger Bands (100)
Buy
Level
3.25 - 4.97
Chaikin Money Flow
Sell
Level
-8.1M
20-day SMA
Sell
Level
$5.32
Relative Strength Index (RSI14)
Sell
Level
46.04
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-78.0083
50-day SMA
Buy
Level
$4.77
MACD (12, 26)
Buy
Level
0.17
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Sell
Level
-19.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0683)
Buy
CA Score
(Annual)
Level (0.4891)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (0.056)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Stock Forecast FAQ
In the current month, PETS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PETS average analyst price target in the past 3 months is --.
-
Where Will PetMed Express Stock Be In 1 Year?
According to analysts, the consensus estimate is that PetMed Express share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About PetMed Express?
Analysts are divided on their view about PetMed Express share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PetMed Express is a Sell and believe this share price will rise from its current level to --.
-
What Is PetMed Express's Price Target?
The price target for PetMed Express over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PETS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PetMed Express is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PETS?
You can purchase shares of PetMed Express via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PetMed Express shares.
-
What Is The PetMed Express Share Price Today?
PetMed Express was last trading at $4.98 per share. This represents the most recent stock quote for PetMed Express. Yesterday, PetMed Express closed at $4.97 per share.
-
How To Buy PetMed Express Stock Online?
In order to purchase PetMed Express stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
